Amgen’s trial brings new hope for IgG4-RD patients
Inebilizumab shows sound efficacy in landmark research
Read More
Tag: Amgen
Amgen’s Otezla shows promise in psoriatic arthritis
The inflammatory form of arthritis is estimated to affect nearly 38 million people worldwide
Read More
Amgen reveals new combination data for KRAS inhibitor
Phase Ib CodeBreaK study evaluated Lumakras in over ten different investigational combination regimens
Read More
Amgen to collab with Verastem on KRAS combination treatment
Agreement will evaluate Verastem’s dual RAF/MEK inhibitor with Amgen’s KRAS G12C inhibitor
Read More
MHRA approves Amgen’s Lumykras under Project Orbis
Project Orbis is an international collaborative programme between the FDA and worldwide regulatory agencies
Read More
New tezepelumab data shows improvements for severe asthma subgroup
TSLP blocker reduced exacerbations in patients with severe asthma and comorbid nasal polyps
Read More
AZ, Amgen’s asthma med tezepelumab gains FDA priority review
Priority review comes following positive results from the Phase III NAVIGATOR trial
Read More
NICE recommends Kyprolis triple combination treatment for multiple myeloma
Kyprolis plus lenalidomide and dexamethasone approved as a second-line treatment
Read More
Amgen looks to expand access to Otezla in the US
Company has submitted a supplemental new drug application for mild-to-moderate plaque psoriasis
Read More
Amgen files KRAS inhibitor sotorasib with EMA
Submission supported by results from phase II CodeBreaK 100 study
Read More
AZ, Amgen’s SOURCE trial misses primary endpoint
New medicine tezepelumab is being studied in severe asthma
Read More
Amgen hands back heart failure programme rights to Cytokinetics
Omecamtiv mecarbil and AMG 594 rights transitioned back to biotech
Read More
- HSE approves new treatment for hidradenitis suppurativa and axial spondyloarthritis
- MSD to acquire Cidara after positive phase 2b trial results
- eXmoor Pharma and Royal Free London link to strengthen UK gene therapy
- Alzheimer’s prevention charity pioneers research on nutrition biomarkers to detect risk
- NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance
